Differential associations of lipoprotein(a) level with cerebral large artery and small vessel diseases

Yuesong Pan, Xueli Cai, Jing Jing, Suying Wang, Xia Meng, Lerong Mei, Yingying Yang, Aoming Jin, Yao DongXiao, Shan Li, Hao Li, Tiemin Wei, Yongjun Wang, Yilong Wang, Yuesong Pan, Xueli Cai, Jing Jing, Suying Wang, Xia Meng, Lerong Mei, Yingying Yang, Aoming Jin, Yao DongXiao, Shan Li, Hao Li, Tiemin Wei, Yongjun Wang, Yilong Wang

Abstract

Background and purpose: Cerebral large artery and small vessel diseases are related to different pathogenetic mechanisms and have different risk factor profile. Lipoprotein(a) (Lp(a)) was shown to promote atherosclerosis but data was limited on its association with cerebral small vessel diseases (cSVD). The objective of this study was to assess the associations of Lp(a) level with the two types of cerebrovascular diseases.

Methods: Community-dwelling subjects aged 50-75 years from the baseline survey of The PolyvasculaR Evaluation for Cognitive Impairment and vaScular Events study were included. Lp(a) concentrations was measured and categorised into three groups according to the tertiles. Eligible participants were scanned by a 3.0T MRI scanner and assessed for intracranial atherosclerosis and cSVD burden based on four imaging markers.

Results: This study included 3059 subjects. The average age of the participants was 61.2±6.7 years, and 53.5% (1636) were female. Compared with the first tertile, subjects with the second and third tertiles of Lp(a) concentrations were associated with an increased odds of presence of intracranial plaque (18.7% vs 15.4%, adj.OR 1.37, 95% CI 1.08 to 1.75; 18.9% vs 15.4%, adj.OR 1.34, 95% CI 1.05 to 1.72). Similar associations were observed for intracranial atherosclerotic burden. Whereas, subjects with the third tertile of Lp(a) level had a decreased odds of presence of cSVD (25.9% vs 31.7%, adj.OR 0.74, 95% CI 0.60 to 0.92) and lower cSVD burden (adj.cOR 0.76, 95% CI 0.62 to 0.94).

Conclusions: In this study, Lp(a) concentrations were positively associated with presence and burden of intracranial atherosclerosis, but was inversely associated with cSVD.

Trial registration number: NCT03178448.

Keywords: Magnetic Resonance Imaging; atherosclerosis; cerebrovascular disorders; plaque.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Figure 1
Figure 1
Flow chart of the participant selection. CSVD, cerebral small vessel disease; Lp(a), lipoprotein(a); PRECISE, PolyvasculaR Evaluation for Cognitive Impairment and vaScular Events.
Figure 2
Figure 2
Distribution of intracranial atherosclerotic and cSVD burden by tertiles of Lp(a) level. Grades 0–4 indicate intracranial atherosclerotic burden score of 0, 1, 2–3 and ≥4, or total cSVD burden score of 0, 1, 2, 3–4, respectively. cSVD, cerebral small vessel disease; Lp(a), lipoprotein(a); T, tertile.
Figure 3
Figure 3
Association of intracranial plaque and cSVD with Lp(a) level. *Model 1 adjusted for age and sex. †Model 2 adjusted for age, sex, body mass index, histories of hypertension, diabetes and atrial fibrillation, current smoking, current drinking, TC, LDLC, HDLC, antihypertensive, antidiabetic, lipid-lowering and anticoagulant agents use. ‡OR and 95% CI for the presence of intracranial plaque and cSVD by binary logistic regression, whereas COR and 95% CI for intracranial atherosclerotic burden and cSVD burden by ordinal logistic regression. §The degree of intracranial atherosclerotic burden was graded as scores of 0, 1, 2–3 and ≥4, respectively. ||The degree of cSVD burden was graded as scores of 0, 1, 2 and 3–4, respectively. COR, common OR; cSVD, cerebral small vessel disease; HDLC, high-density lipoprotein cholesterol; Lp(a), lipoprotein(a); LDLC, low-density lipoprotein cholesterol; Ref., reference; T, tertile; TC, total cholesterol.
Figure 4
Figure 4
Forest plots for the association between Lp(a) level and cSVD imaging markers. The plots showed the OR and their 95% CIs. BG-PVS, basal ganglia-enlarged perivascular spaces; CMBs, cerebral microbleeds; cSVD, cerebral small vessel disease; Lp(a), lipoprotein(a); T, tertile; WHM, white matter hyperintensities.
Figure 5
Figure 5
ORs/ common ORs of intracranial plaque and cSVD according to Lp(a) level. (A) Presence of intracranial plaque; (B) intracranial atherosclerotic burden; (C) presence of cSVD; (D) cSVD burden. Lp(a) level of 40 mg/L (33rd percentile) was set as reference. Data were fitted using a binary or ordinal logistic regression with restricted cubic spline. cSVD, cerebral small vessel disease; Lp(a), lipoprotein(a).

References

    1. Pan Y, Li H, Wardlaw JM, et al. . A new dawn of preventing dementia by preventing cerebrovascular diseases. BMJ 2020;371:m3692. 10.1136/bmj.m3692
    1. Del Brutto OH, Mera RM, Del Brutto VJ, et al. . Cerebral small vessel disease score and atherosclerosis burden - A population study in community-dwelling older adults. Clin Neurol Neurosurg 2020;194:105795. 10.1016/j.clineuro.2020.105795
    1. Khan U, Porteous L, Hassan A, et al. . Risk factor profile of cerebral small vessel disease and its subtypes. J Neurol Neurosurg Psychiatry 2007;78:702–6. 10.1136/jnnp.2006.103549
    1. Feng C, Bai X, Xu Y, et al. . Hyperhomocysteinemia associates with small vessel disease more closely than large vessel disease. Int J Med Sci 2013;10:408–12. 10.7150/ijms.5272
    1. Shu M-J, Zhai F-F, Zhang D-D, et al. . Metabolic syndrome, intracranial arterial stenosis and cerebral small vessel disease in community-dwelling populations. Stroke Vasc Neurol 2021;6:589–94. 10.1136/svn-2020-000813
    1. Kotani K, Serban M-C, Penson P, et al. . Evidence-based assessment of lipoprotein(a) as a risk biomarker for cardiovascular diseases - Some answers and still many questions. Crit Rev Clin Lab Sci 2016;53:370–8. 10.1080/10408363.2016.1188055
    1. Emerging Risk Factors Collaboration, Erqou S, Kaptoge S, et al. . Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009;302:412–23. 10.1001/jama.2009.1063
    1. Larsson SC, Gill D, Mason AM, et al. . Lipoprotein(a) in Alzheimer, Atherosclerotic, Cerebrovascular, Thrombotic, and Valvular Disease: Mendelian Randomization Investigation. Circulation 2020;141:1826–8. 10.1161/CIRCULATIONAHA.120.045826
    1. Burgess S, Ference BA, Staley JR, et al. . Association of LPA Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies: A Mendelian Randomization Analysis. JAMA Cardiol 2018;3:619–27. 10.1001/jamacardio.2018.1470
    1. Saleheen D, Haycock PC, Zhao W, et al. . Apolipoprotein(a) isoform size, lipoprotein(a) concentration, and coronary artery disease: a mendelian randomisation analysis. Lancet Diabetes Endocrinol 2017;5:524–33. 10.1016/S2213-8587(17)30088-8
    1. Trinder M, Uddin MM, Finneran P, et al. . Clinical Utility of Lipoprotein(a) and LPA Genetic Risk Score in Risk Prediction of Incident Atherosclerotic Cardiovascular Disease. JAMA Cardiol 2021;6:287–95. 10.1001/jamacardio.2020.5398
    1. Steffen BT, Thanassoulis G, Duprez D, et al. . Race-Based Differences in Lipoprotein(a)-Associated Risk of Carotid Atherosclerosis. Arterioscler Thromb Vasc Biol 2019;39:523–9. 10.1161/ATVBAHA.118.312267
    1. van Dam-Nolen DHK, van Dijk AC, Crombag GAJC, et al. . Lipoprotein(a) levels and atherosclerotic plaque characteristics in the carotid artery: The Plaque at RISK (PARISK) study. Atherosclerosis 2021;329:22–9. 10.1016/j.atherosclerosis.2021.06.004
    1. Cerrato P, Imperiale D, Fornengo P, et al. . Higher lipoprotein (a) levels in atherothrombotic than lacunar ischemic cerebrovascular disease. Neurology 2002;58:653–5. 10.1212/WNL.58.4.653
    1. Arora P, Kalra R, Callas PW, et al. . Lipoprotein(a) and Risk of Ischemic Stroke in the REGARDS Study. Arterioscler Thromb Vasc Biol 2019;39:810–8. 10.1161/ATVBAHA.118.311857
    1. Langsted A, Nordestgaard BG, Kamstrup PR. Elevated Lipoprotein(a) and Risk of Ischemic Stroke. J Am Coll Cardiol 2019;74:54–66. 10.1016/j.jacc.2019.03.524
    1. Yu X, Yu Y, Wei C, et al. . Association between small dense low-density lipoprotein cholesterol and neuroimaging markers of cerebral small vessel disease in middle-aged and elderly Chinese populations. BMC Neurol 2021;21:436. 10.1186/s12883-021-02472-6
    1. Iskra T, Turaj W, Słowik A, et al. . [Lipoprotein (a) in stroke patients with large and small vessel disease]. Przegl Lek 2002;59:877–80.
    1. Pan Y, Li H, Wang Y, et al. . Causal Effect of Lp(a) [Lipoprotein(a)] Level on Ischemic Stroke and Alzheimer Disease: A Mendelian Randomization Study. Stroke 2019;50:3532–9. 10.1161/STROKEAHA.119.026872
    1. Pan Y, Jing J, Cai X, et al. . PolyvasculaR Evaluation for Cognitive Impairment and vaScular Events (PRECISE)-a population-based prospective cohort study: rationale, design and baseline participant characteristics. Stroke Vasc Neurol 2021;6:e000411–51. 10.1136/svn-2020-000411
    1. Xu L, Schooling CM, Chan WM, et al. . Smoking and hemorrhagic stroke mortality in a prospective cohort study of older Chinese. Stroke 2013;44:2144–9. 10.1161/STROKEAHA.113.001500
    1. Wang Z, Chen Z, Zhang L, et al. . Status of hypertension in China: results from the China hypertension survey, 2012-2015. Circulation 2018;137:2344–56. 10.1161/CIRCULATIONAHA.117.032380
    1. Wang L, Gao P, Zhang M, et al. . Prevalence and ethnic pattern of diabetes and prediabetes in China in 2013. JAMA 2017;317:2515–23. 10.1001/jama.2017.7596
    1. Qiao Y, Guallar E, Suri FK, et al. . Mr imaging measures of intracranial atherosclerosis in a population-based study. Radiology 2016;280:860–8. 10.1148/radiol.2016151124
    1. Samuels OB, Joseph GJ, Lynn MJ, et al. . A standardized method for measuring intracranial arterial stenosis. AJNR Am J Neuroradiol 2000;21:643–6.
    1. Sun P, Liu L, Pan Y, et al. . Intracranial atherosclerosis burden and stroke recurrence for symptomatic intracranial artery stenosis (sICAS). Aging Dis 2018;9:1096–102. 10.14336/AD.2018.0301
    1. Wardlaw JM, Smith EE, Biessels GJ, et al. . Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol 2013;12:822–38. 10.1016/S1474-4422(13)70124-8
    1. Fazekas F, Chawluk JB, Alavi A, et al. . MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. AJR Am J Roentgenol 1987;149:351–6. 10.2214/ajr.149.2.351
    1. Greenberg SM, Vernooij MW, Cordonnier C, et al. . Cerebral microbleeds: a guide to detection and interpretation. Lancet Neurol 2009;8:165–74. 10.1016/S1474-4422(09)70013-4
    1. Staals J, Makin SDJ, Doubal FN, et al. . Stroke subtype, vascular risk factors, and total MRI brain small-vessel disease burden. Neurology 2014;83:1228–34. 10.1212/WNL.0000000000000837
    1. Helgadottir A, Gretarsdottir S, Thorleifsson G, et al. . Apolipoprotein(a) genetic sequence variants associated with systemic atherosclerosis and coronary atherosclerotic burden but not with venous thromboembolism. J Am Coll Cardiol 2012;60:722–9. 10.1016/j.jacc.2012.01.078
    1. Arenillas JF, Molina CA, Chacón P, et al. . High lipoprotein (a), diabetes, and the extent of symptomatic intracranial atherosclerosis. Neurology 2004;63:27–32. 10.1212/01.WNL.0000132637.30287.B4
    1. Yuan B-B, Luo G-G, Gao J-X, et al. . Variance of serum lipid levels in stroke subtypes. Clin Lab 2015;61:1509–14. 10.7754/Clin.Lab.2015.150118
    1. Shu Z, Xu Y, Shao Y, et al. . Radiomics from magnetic resonance imaging may be used to predict the progression of white matter hyperintensities and identify associated risk factors. Eur Radiol 2020;30:3046–58. 10.1007/s00330-020-06676-1
    1. Schilling S, Tzourio C, Dufouil C, et al. . Plasma lipids and cerebral small vessel disease. Neurology 2014;83:1844–52. 10.1212/WNL.0000000000000980
    1. Pepe G, Chimienti G, Liuzzi GM, et al. . Lipoprotein(a) in the cerebrospinal fluid of neurological patients with blood-cerebrospinal fluid barrier dysfunction. Clin Chem 2006;52:2043–8. 10.1373/clinchem.2006.073544
    1. Saczynski JS, White L, Peila RL, et al. . The relation between apolipoprotein A-I and dementia: the Honolulu-Asia aging study. Am J Epidemiol 2007;165:985–92. 10.1093/aje/kwm027
    1. Kunutsor SK, Khan H, Nyyssönen K, et al. . Is lipoprotein (a) protective of dementia? Eur J Epidemiol 2016;31:1149–52. 10.1007/s10654-016-0184-0
    1. IWAMOTO T, WATANABE D, UMAHARA T, et al. . Dual inverse effects of lipoprotein(a) on the dementia process in Japanese late-onset Alzheimer’s disease. Psychogeriatrics 2004;4:64–71. 10.1111/j.1479-8301.2004.00063.x
    1. Schilling S, DeStefano AL, Sachdev PS, et al. . Apoe genotype and MRI markers of cerebrovascular disease: systematic review and meta-analysis. Neurology 2013;81:292–300. 10.1212/WNL.0b013e31829bfda4

Source: PubMed

3
Předplatit